{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Bronchogenic&page=87", "query": { "condition": "Carcinoma, Bronchogenic", "page": 87 }, "page_size": 10 }, "pagination": { "page": 87, "page_size": 10, "total_count": 3602, "total_pages": 361, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Bronchogenic&page=88&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Bronchogenic&page=86&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-02T13:19:12.826Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00697060", "title": "A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Imexon + docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AmpliMed Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2010-08", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2015-06-24", "last_synced_at": "2026-11-02T13:19:12.826Z", "location_count": 3, "location_summary": "Los Angeles, California • Boston, Massachusetts • Dallas, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00697060" }, { "nct_id": "NCT06077760", "title": "A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Intismeran autogene", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 868, "start_date": "2023-12-06", "completion_date": "2035-12-21", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-11-02T13:19:12.826Z", "location_count": 68, "location_summary": "Anchorage, Alaska • Tucson, Arizona • Yuma, Arizona + 55 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Yuma", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06077760" }, { "nct_id": "NCT06236438", "title": "Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Livmoniplimab", "type": "DRUG" }, { "name": "Budigalimab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 167, "start_date": "2024-04-10", "completion_date": "2031-10", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-11-02T13:19:12.826Z", "location_count": 19, "location_summary": "La Jolla, California • Pembroke Pines, Florida • Winter Haven, Florida + 16 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Winter Haven", "state": "Florida" }, { "city": "Athens", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06236438" }, { "nct_id": "NCT03731585", "title": "Online Psychosocial Intervention in Improving Social Well-Being and Support in Women With Stage I-IV Non-small Cell Lung Cancer Undergoing Treatment", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Non-Small Cell Lung Carcinoma", "Stage I Lung Cancer AJCC v8", "Stage IA1 Lung Cancer AJCC v8", "Stage IA2 Lung Cancer AJCC v8", "Stage IA3 Lung Cancer AJCC v8", "Stage IB Lung Cancer AJCC v8", "Stage II Lung Cancer AJCC v8", "Stage IIA Lung Cancer AJCC v8", "Stage IIB Lung Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Behavioral Intervention", "type": "BEHAVIORAL" }, { "name": "Educational Intervention", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Support Group Therapy", "type": "PROCEDURE" } ], "intervention_types": [ "BEHAVIORAL", "OTHER", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 70, "start_date": "2018-11-15", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-11-02T13:19:12.826Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03731585" }, { "nct_id": "NCT01761240", "title": "Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Pancreatic Cancer", "Colorectal Cancer", "Carcinoma, Non-Small-Cell Lung", "Adenocarcinoma" ], "interventions": [ { "name": "MORAb-066", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Morphotek", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 27, "start_date": "2013-06-19", "completion_date": "2016-02-09", "has_results": true, "last_update_posted_date": "2024-03-29", "last_synced_at": "2026-11-02T13:19:12.826Z", "location_count": 2, "location_summary": "Oklahoma City, Oklahoma • Nashville, Tennessee", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01761240" }, { "nct_id": "NCT04187768", "title": "Immunological Profile Changes In Patients With Advanced Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Non Small Cell Lung Cancer", "Non Small Cell Lung Cancer Metastatic", "Healthy" ], "interventions": [], "intervention_types": [], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2019-11-26", "completion_date": "2022-06-13", "has_results": false, "last_update_posted_date": "2022-07-20", "last_synced_at": "2026-11-02T13:19:12.826Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04187768" }, { "nct_id": "NCT00511576", "title": "Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Lung Cancer", "Pulmonary Cancer", "Non-Small-Cell Lung Carcinoma", "Prostate Cancer", "Prostatic Cancer", "Gastric Cancer", "Stomach Cancer" ], "interventions": [ { "name": "MGCD0103 & Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirati Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2007-08", "completion_date": "2009-03", "has_results": false, "last_update_posted_date": "2015-01-08", "last_synced_at": "2026-11-02T13:19:12.826Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Philadelphia, Pennsylvania", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00511576" }, { "nct_id": "NCT02453282", "title": "Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small-Cell Lung Carcinoma NSCLC" ], "interventions": [ { "name": "MEDI4736 (Durvalumab)", "type": "BIOLOGICAL" }, { "name": "MEDI4736 (Durvalumab)+Tremelimumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel + Carboplatin", "type": "DRUG" }, { "name": "Gemcitabine + Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine + Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed + Cisplatin", "type": "DRUG" }, { "name": "Pemetrexed + Carboplatin", "type": "DRUG" }, { "name": "Tremelimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 1118, "start_date": "2015-07-21", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-11-02T13:19:12.826Z", "location_count": 35, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Yuma, Arizona + 28 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Yuma", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02453282" }, { "nct_id": "NCT05329623", "title": "A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Small Cell Lung Carcinoma" ], "interventions": [ { "name": "JDQ443", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 33, "start_date": "2022-05-03", "completion_date": "2024-04-07", "has_results": false, "last_update_posted_date": "2025-10-10", "last_synced_at": "2026-11-02T13:19:12.826Z", "location_count": 2, "location_summary": "Orlando, Florida • San Antonio, Texas", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05329623" }, { "nct_id": "NCT00622674", "title": "Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Colorectal Cancer", "Head and Neck Cancer", "Kidney Cancer", "Lung Cancer", "Pancreatic Cancer", "Sarcoma", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "bortezomib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2005-11", "completion_date": "2010-02", "has_results": false, "last_update_posted_date": "2017-12-02", "last_synced_at": "2026-11-02T13:19:12.826Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00622674" } ] }